Cost-effectiveness analyses of amivantamab plus lazertinib and lazertinib versus osimertinib in non-small cell lung cancer with EGFR mutations

BackgroundThe combination of amivantamab and lazertinib has demonstrated clinically significant and sustained antitumor effects in both treatment-naïve and osimertinib-pretreated advanced non-small cell lung cancer (NSCLC) patients harboring previously untreated epidermal growth factor receptor (EGF...

Descripció completa

Dades bibliogràfiques

Autors principals:	Hui Zhang, Yueyun Li, Yuhang Liu, Haonan Li, Hong Wang
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2025-05-01
Col·lecció:	Frontiers in Pharmacology
Matèries:	amivantamab lazertinib osimertinib cost-effectiveness analysis non-small cell lung cancer
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1527614/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!